Accelerating Biomedical Technologies from Incubation to Monetization 0 Investor MARCH 2017 2017 Presentation Q BIO
Forward Looking Statements This presentation contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentation which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. These forward-looking statements generally can be identified by phrases such as Q BioMed, Inc. (“QBIO”) or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar importance. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those project these forward-looking statements are made as of the date of this presentation, and we assume no obligation to update any forward-looking statements due to numerous factors. forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this presentation are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should review all of the information set forth herein, and should also understand the risk factors and the inherent uncertainties associated with new business opportunities and development stage. Any use of this information for any purpose other than in connection with the consideration of an investment in Q BioMed, Inc companies. (“QBIO”) may subject the user to criminal and civil liability. This presentation does not constitute an offer to sell any securities or the solicitation of an offer to sell any securities by Q BioMed Inc.
Biotech Growth & The Problem It Created Q BioMed Solves It by Accessing Undiscovered Biomedical Technologies for Investment t
The Biotech & The Life Pharma Sales Linked to 60+ Population Science Sectors Sales $M 60+ Population 1200 1000 800 Pharma sales continue on a five-year growth track 600 and is expected long term. 400 200 An aging population provides consistent demand 0 and high growth rates. 2010 2011 2012 2013 2014 2015 Sources: UNDESA Population and Pharmafile Demand for affordable drugs remains inelastic. Global Biotech Market Estimate International market growth creates a positive Global Market Growth Estimate 500 USD $B 450 400 350 300 However, the reality for many is 250 200 approximately 8 out of 10 biomedical ideas 150 100 50 are under-recognized and under-capitalized. 0 2015 2016 2017 2018 2019 Only very few have access to capital leaving viable ideas unfunded and neglected. Sources: UNDESA Population and Pharmafile p. 4
The Problem 80 80 % of biomedical start ups lack capital and resources to transition from incubation to development and beyond . Reasons Too small Unrealistic goals Unproven IP/ formulation Missed milestones Not ready to go public Previous financing Cannot attract / retain talent Not attracting partnerships The Result Billions of dollars in market value remain locked in academia, early- stage IP, unfocused management, challenging capital structures and failed IPOs. Investors cannot access them. They live in limbo or stuck in ‘dead money’ investments. Q BioMed Solves the Problem by availing capital to develop biomedical technologies while also providing investors access to participate in our assets' growth and value. p. 5
Our vision is to create a pipeline of innovative biomedical assets in various stages of development in multiple therapeutic areas. Our strategy will minimize risk, share success and accelerate our assets' technologies to monetization.
Management Team GRAH 1 Denis Denis Corin Corin William illiam Rosenstadt osenstadt David Da vid Lask Laskow-Pooley ooley Ari Ari Jatw twes es Chief Executive Officer General Counsel VP Product Development Analyst Chairman of the Board Director Director Director Asset Search and Due Diligence Ongoing Since Inception Our Milestones 2015 2016 2017 February September November Planned April June October August September SR89 Exclusive Closes SR89 1Q 2017 $4 M Initiated new MAN-01 Exclusive MAN-01 Established Engages Wombat License Option LOI License Option initial Sr89 Molecule Opt . Financing Management Team License Option business model Capital as Scientific production Advisor Advisory Board Dr. Geert Cauwenberg Dr. Helga Grupe Dr. Jose de Chastonay Dr. Scott P Bruder Andy Watson John Erb Dermatology, Wound, Infectious Oncology Contract Services Medical Devices, Orthopedics Diagnostics, Companions, Medical Device Diseases, Women’s Health and Regenerative Medicine Genomics, Life Science Tools Cardio Vascular Mary Jan Rafii Dr. Susan Quaggin George Nikopoulos Rosanne Satz Dr. Stanley Satz Jean-Jaques Ophthalmology CSO, Manin Resarch CEO, Mannin Research CEO, BioNucleonics, Chairman, BioNucleonics Mondoloni Advisor Wombat Capital p. 7
How We Accelerate Biomedical Technology Development We unlock capital through US public markets to fund the development of our assets. We make liquid investments in high-value assets that can produce exponential returns. We diversifiy risk over several therapies in various stages of development and deploy performance- based capital only. We accelerate our assets' development with our management and advisory teams' expertise, experience, and industry relationships. Our ownership of an asset and our ROI steadily increase as assets hit milestones and cross value-creating events during development lifecycles.
Our Business Model Preliminary scientific and commercial criteria review. IDENTIFY Determining management's expectations and flexibility moves the asset to the next step. Criteria match and fit ANALYZE Due diligence is combined with a validation of management's development and capital requirements. Asset and development plan INVEST Performance-based capital is deployed to meet specific and mutually-agreed goals in each stage. Capital attached to goals ACCELERATE Additional resources are infused to move the asset through development stages and to a value-creating inflection point. Increase investment and ownership MONETIZE Assets can be sold, licensed, joint-ventured or operated as cash flow positive product lines. QBIO's goal is to maximize value for its shareholders. Operate, partner, license, IPO or sell
The Importance of an Asset's Development Plan A Requirement to Access QBio Capital Development plans provide QBio a tool to assess management's work to date and an insight into an asset's biomedical technology and value. The plan should have clearly defined milestones and quantify capital needed to accelerate development. QBIO's Team and Advisors can pinpoint their resources to help transition a plan through development to monetization. Managing to milestones mitigates investment risk. QBio's capital is released only when milestones are met.
A Growing Pipeline Mitigates Risk and Drives Shareholder Value Drug Candidate Preclinical Phase 1 Phases 1b/2a Phase 3 Approval ASSET 1 SR-89 Radiopharmaceutical ASSET 2 MAN – 01 Topical Eye Drops ASSET 3 UTTROCIDE-B Chemotherapy TARGET ASSET 4 Drug Candidate 505(b)2 Preclinical Phase 1 Phases 2/3 Phase 4 Approval TARGET ASSET 5 Protocol Design for Ph4 TARGET ASSET 6 IND Preparation for Ph2/3 In YEARS 1&2 we are focused on licensing and acquiring assets, some with near term (6-12 months) REVENUE or value-creating opportunities. In YEARS 2&3 we will look to grow the pipeline and monetize investments through partnerships, JV, IPO and sales revenue growth. p. 11
Strontium Chloride Sr89 Injection, USP UTTROCIDE- B Our Current Portfolio of High-Value Assets FDA-Approved, Commercialization Planning and Accelerating Development of Additional Large-Market Therapies
Asset 1 Pharmaceutical: Generic SR-89 Radiopharmaceutical Condition: Bone Cancer Therapy and Pain Management Addressable ~110,000 yearly Market: diagnoses from breast and prostate cancers Technology BioNucleonics Stage: - Approved Commercializing Strontium Chloride Sr89 Injection, USP
BONE METASTESES from Prostate and Breast Cancer ▪ 450,000* new breast and prostate cases are recorded each year ▪ 1 in 3 people 1 in 3 people will develop bone metastases from the spread of breast and prostate cancer Pain Management ▪ Pain is the most common sign of bone cancer, and may become more noticeable as the tumor grows. ▪ Bone pain can cause a dull or dull or deep ac deep ache he in a bone or bone region (e.g., back, pelvis, legs, ribs, arms). ▪ Treatment options include: Pain Medications - Opioids Orthopedic Procedures Radiation Therapy Radiopharmaceuticals ▪ Sr89 is Sr89 is NON NON-NAR ARCO COTI TIC C and can mitiga and can mitigate opi te opioid oid use and a use and abuse buse p. 14 *Source: American Cancer Society, 2016
Recommend
More recommend
